Orphazyme20.jpg

INVESTORS & MEDIA

Investors & Media

INVESTORS & MEDIA

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC).

We are committed to providing relevant, accurate and timely information to investors and the financial community. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH).

 

Latest Announcements

Share Price

Read more

Upcoming Events

Date Event Details
Summary Toggle 21/05/2022

Annual General Meeting 2022 (No later than 1 month after the completion of the ongoing in-court restructuring proceedings)

No later than 1 month after the completion of the ongoing in-court restructuring proceedings
Summary Toggle 25/08/2022

Interim Report First Half 2022
Read more

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Sign up here

IR Contact

anders

Anders Vadsholt

CEO & CFOTel: (+45) 28 98 90 55E-mail: afv@orphazyme.com